Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

1.

Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications.

Seo W, Kapralov AA, Shurin GV, Shurin MR, Kagan VE, Star A.

Nanoscale. 2015 Apr 23. [Epub ahead of print]

PMID:
25902750
2.

MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes.

Shvedova AA, Kisin ER, Yanamala N, Tkach AV, Gutkin DW, Star A, Shurin GV, Kagan VE, Shurin MR.

Cancer Res. 2015 Apr 15;75(8):1615-23. doi: 10.1158/0008-5472.CAN-14-2376. Epub 2015 Mar 5.

PMID:
25744719
3.

Nano-gold corking and enzymatic uncorking of carbon nanotube cups.

Zhao Y, Burkert SC, Tang Y, Sorescu DC, Kapralov AA, Shurin GV, Shurin MR, Kagan VE, Star A.

J Am Chem Soc. 2015 Jan 21;137(2):675-84. doi: 10.1021/ja511843w. Epub 2015 Jan 7.

PMID:
25530234
4.

C-reactive protein and lung diseases.

Agassandian M, Shurin GV, Ma Y, Shurin MR.

Int J Biochem Cell Biol. 2014 Aug;53:77-88. doi: 10.1016/j.biocel.2014.05.016. Epub 2014 May 19. Review.

PMID:
24853773
5.

Graphene oxide attenuates Th2-type immune responses, but augments airway remodeling and hyperresponsiveness in a murine model of asthma.

Shurin MR, Yanamala N, Kisin ER, Tkach AV, Shurin GV, Murray AR, Leonard HD, Reynolds JS, Gutkin DW, Star A, Fadeel B, Savolainen K, Kagan VE, Shvedova AA.

ACS Nano. 2014 Jun 24;8(6):5585-99. doi: 10.1021/nn406454u. Epub 2014 May 23.

PMID:
24847914
6.

Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Zhong H, Gutkin DW, Han B, Ma Y, Keskinov AA, Shurin MR, Shurin GV.

Int J Cancer. 2014 Jun 1;134(11):2633-45. doi: 10.1002/ijc.28590. Epub 2014 Jan 20.

7.

Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Landreneau JP, Shurin MR, Agassandian MV, Keskinov AA, Ma Y, Shurin GV.

Cancer Microenviron. 2013 Nov 29. [Epub ahead of print]

PMID:
24293116
8.

Early growth response-2 signaling mediates immunomodulatory effects of human multipotential stromal cells.

Barbeau DJ, La KT, Kim DS, Kerpedjieva SS, Shurin GV, Tamama K.

Stem Cells Dev. 2014 Jan 15;23(2):155-66. doi: 10.1089/scd.2013.0194. Epub 2013 Oct 5.

9.

Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Shurin GV, Ma Y, Shurin MR.

Cancer Microenviron. 2013 Aug;6(2):159-67. doi: 10.1007/s12307-013-0133-3. Epub 2013 Jun 9.

10.

The role of TLR4 in the paclitaxel effects on neuronal growth in vitro.

Ustinova EE, Shurin GV, Gutkin DW, Shurin MR.

PLoS One. 2013;8(2):e56886. doi: 10.1371/journal.pone.0056886. Epub 2013 Feb 18.

11.

Dendritic cells in the cancer microenvironment.

Ma Y, Shurin GV, Peiyuan Z, Shurin MR.

J Cancer. 2013;4(1):36-44. doi: 10.7150/jca.5046. Epub 2012 Dec 15.

12.

Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.

Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V.

J Immunol. 2013 Mar 1;190(5):2464-71. doi: 10.4049/jimmunol.1202781. Epub 2013 Jan 28.

13.

Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells.

Shvedova AA, Tkach AV, Kisin ER, Khaliullin T, Stanley S, Gutkin DW, Star A, Chen Y, Shurin GV, Kagan VE, Shurin MR.

Small. 2013 May 27;9(9-10):1691-5. doi: 10.1002/smll.201201470. Epub 2012 Sep 20.

14.

Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells.

Tkach AV, Yanamala N, Stanley S, Shurin MR, Shurin GV, Kisin ER, Murray AR, Pareso S, Khaliullin T, Kotchey GP, Castranova V, Mathur S, Fadeel B, Star A, Kagan VE, Shvedova AA.

Small. 2013 May 27;9(9-10):1686-90. doi: 10.1002/smll.201201546. Epub 2012 Aug 13.

15.

Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice.

Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin GV, Umansky V.

J Immunotoxicol. 2012 Jul-Sep;9(3):275-81. doi: 10.3109/1547691X.2012.655343. Epub 2012 Mar 27.

PMID:
22449053
16.

Tumor associated regulatory dendritic cells.

Ma Y, Shurin GV, Gutkin DW, Shurin MR.

Semin Cancer Biol. 2012 Aug;22(4):298-306. doi: 10.1016/j.semcancer.2012.02.010. Epub 2012 Mar 6. Review.

17.

ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.

Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV.

Curr Med Chem. 2012;19(12):1792-803. Review.

PMID:
22414087
18.

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.

Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR.

J Immunotoxicol. 2012 Jul-Sep;9(3):292-300. doi: 10.3109/1547691X.2011.642418. Epub 2012 Jan 28.

19.

Regulatory dendritic cells in the tumor immunoenvironment.

Shurin GV, Ouellette CE, Shurin MR.

Cancer Immunol Immunother. 2012 Feb;61(2):223-30. doi: 10.1007/s00262-011-1138-8. Epub 2011 Nov 8. Review.

20.

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.

Naiditch H, Shurin MR, Shurin GV.

Immunol Res. 2011 Aug;50(2-3):276-85. doi: 10.1007/s12026-011-8213-2.

PMID:
21717082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk